Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial
Authors
Keywords
-
Journal
Gastric Cancer
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-29
DOI
10.1007/s10120-021-01258-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Japanese gastric cancer treatment guidelines 2018 (5th edition)
- (2020) Gastric Cancer
- White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
- (2020) Alessandro Leal et al. Nature Communications
- Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer
- (2020) Jian Yang et al. Cell Death & Disease
- Towards Personalization in the Curative Treatment of Gastric Cancer
- (2020) Astrid E. Slagter et al. Frontiers in Oncology
- Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma
- (2019) Rosa T. van der Kaaij et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Life and death of circulating cell-free DNA
- (2019) Anatoli Kustanovich et al. CANCER BIOLOGY & THERAPY
- Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer
- (2019) Tej D. Azad et al. GASTROENTEROLOGY
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
- (2018) Annemieke Cats et al. LANCET ONCOLOGY
- Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer
- (2018) Tsutomu Namikawa et al. Gastric Cancer
- Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
- (2017) Charles S. Fuchs et al. Journal of Gastric Cancer
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
- (2016) Elizabeth C. Smyth et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms
- (2016) Zi-Xian Wang et al. Oncotarget
- Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis
- (2015) Yong-xi Song et al. DISEASE MARKERS
- The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients
- (2015) Kai Deng et al. PLoS One
- The Clinicopathologic Importance of Serum Lactic Dehydrogenase in Patients with Gastric Cancer
- (2014) Zhi Zhao et al. DISEASE MARKERS
- Clinicopathological Significance and Prognostic Value of Lactate Dehydrogenase A Expression in Gastric Cancer Patients
- (2014) Xuren Sun et al. PLoS One
- Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
- (2011) Johan L Dikken et al. BMC CANCER
- A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
- (2010) D. Kanagavel et al. ANNALS OF ONCOLOGY
- Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram
- (2010) Vivian E. Strong et al. ANNALS OF SURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now